A 12-Week Study to Evaluate the Safety, Tolerability and Effects of danuglipron in Adults With Type 2 Diabetes Mellitus Treated With Metformin and Non-Diabetic Adults With Obesity. A 12-Week, Phase 2A, Randomized, Double-Blind,
Sponsor-Open, Placebo-Controlled, Parallel Group Study to Assess the Safety, Tolerability, and Pharmacodynamics of PF-06882961 Titration in Adults With Type 2 Diabetes Mellitus Treated With Metformin and in Non-Diabetic Adults With Obesity.